Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption

Rhea-AI Summary

Microbot Medical (NASDAQ: MBOT) will showcase the LIBERTY Endovascular Robotic System at the Society of Interventional Oncology meeting in Savannah, Feb 4-8, 2026. The company is in a limited market release started late 2025 and will give hands-on demos to accelerate adoption ahead of a planned full release in April 2026.

LIBERTY is FDA cleared as a single-use, remotely operated robotic system for peripheral endovascular procedures, designed to improve navigation and reduce radiation exposure and operator strain.

Key Figures

Conference dates: February 4–8, 2026 Limited release timing: Late 2025 Planned full release: April 2026

3 metrics

Conference dates February 4–8, 2026 Society of Interventional Oncology annual meeting window

Limited release timing Late 2025 Commencement of LIBERTY limited market release

Planned full release April 2026 Targeted full market release at SIR conference

Market Reality Check

Price: $1.62 Vol: Volume 1,181,534 is close...

normal vol

$1.62 Last Close

Volume Volume 1,181,534 is close to the 20-day average of 1,161,209, indicating typical liquidity ahead of this news. normal

Technical Shares at $1.74 are trading below the 200-day MA of $2.61 and about 62.74% under the 52-week high of $4.67.

Peers on Argus

While MBOT was down 3.33% ahead of this oncology conference update, several peer...

While MBOT was down 3.33% ahead of this oncology conference update, several peers such as AVR, KRMD, INFU, and STXS also showed single‑day declines between 5–9%, suggesting broader pressure in medical instruments even though the momentum scanner did not flag this as a coordinated sector move.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Milestones update	Positive	+1.9%	Outlined 2025 progress and key 2026 milestones for LIBERTY commercialization.
Nov 26	First adopter hospital	Positive	+21.8%	Emory University Hospital became first LIBERTY adopter and robotics program partner.
Nov 05	Limited market launch	Positive	+5.0%	Announced U.S. limited market release of LIBERTY following FDA 510(k) clearance.
Oct 16	Conference debut	Positive	-2.7%	Planned first commercial exhibition of LIBERTY at clinical interventional oncology meeting.
Oct 14	Logistics partnership	Positive	-4.3%	Secured U.S. logistics partner to support upcoming LIBERTY commercialization phases.

Pattern Detected

Commercial and milestone updates around LIBERTY have more often produced positive price reactions, though some commercialization and logistics headlines have seen short‑term selloffs.

Recent Company History

Over the past few months, Microbot has repeatedly highlighted commercialization steps for the LIBERTY system, including its limited market release, Emory University Hospital as the first adopter, and progress milestones outlined on Jan 12, 2026. Earlier updates in October–November 2025 covered initial commercial availability, logistics build‑out, and debut conference exhibitions. Today’s announcement about leveraging current user experience at a major oncology meeting fits this pattern of using conferences and early adopters to build awareness ahead of the broader launch planned at the Society of Interventional Radiology conference in April 2026.

Regulatory & Risk Context

Active S-3 Shelf · $25,000.00

Shelf Active

Active S-3 Shelf Registration 2025-10-28

$25,000.00 registered capacity

An amended Form S-3 shelf registration filed on Oct 28, 2025 added Rule 473(b) language and listed offering-related expenses of $25,000.00. The shelf shows an established framework for potential future securities offerings and has already supported 2 prospectus supplements filed on Nov 19, 2025.

Market Pulse Summary

This announcement highlights Microbot’s strategy of using the Society of Interventional Oncology mee...

Analysis

This announcement highlights Microbot’s strategy of using the Society of Interventional Oncology meeting to showcase LIBERTY through hands-on demonstrations and real-world user experience during its limited market release. It follows prior milestones such as FDA clearance, logistics build‑out, and first‑site adoption, all leading toward the planned full market release at the SIR conference in April 2026. Investors may monitor physician feedback, adoption breadth, and subsequent regulatory or capital markets updates as key follow-on data points.

Key Terms

endovascular, interventional oncology, interventional radiology, peripheral endovascular procedures, +1 more

5 terms

endovascular medical

"LIBERTY® Endovascular Robotic System, announced that it is attending..."

Endovascular describes medical procedures performed inside blood vessels using thin tubes, wires, and implantable devices guided by imaging—like repairing a broken pipe from the inside rather than opening the wall. It matters to investors because these less-invasive techniques can shorten hospital stays, lower complication rates and create demand for specialized devices and imaging equipment, so changes in adoption, regulation or reimbursement can materially affect healthcare company revenues and margins.

interventional oncology medical

"engage with interventional oncologists with the goal of accelerating..."

Interventional oncology is a branch of medicine that uses image-guided, minimally invasive procedures to treat cancer by targeting tumors directly—through techniques such as precise heat, cold, chemical delivery, or blocking a tumor's blood supply. Investors care because it drives demand for specialized devices, hospital services and repeatable outpatient procedures, and can change treatment costs and patient outcomes much like a targeted tool that removes a weed without digging up the whole garden.

interventional radiology medical

"interventional oncology serving as a key value driver in interventional radiology"

Interventional radiology is a medical specialty that uses imaging tools (like X-rays, CT scans or ultrasound) as a live map to guide tiny instruments through small skin openings to diagnose or treat problems inside the body, replacing larger surgeries. For investors, it matters because these image-guided procedures often cut recovery time, reduce hospital stays and create steady demand for specialized devices, imaging equipment and related services, affecting healthcare costs and industry revenues.

peripheral endovascular procedures medical

"robotic system for peripheral endovascular procedures, and it is designed..."

Minimally invasive treatments that repair or open narrowed, blocked or damaged blood vessels outside the heart and brain by threading small tools through the vessel—think of fixing a clogged pipe from the inside using balloons, tiny cutters or scaffolds. Investors care because these procedures drive sales for medical devices, hospital revenue and recurring consumables, and their growth depends on aging populations, reimbursement rules and regulatory approvals that affect company earnings and adoption rates.

radiation exposure medical

"designed for precise vascular navigation while aiming to reduce radiation exposure"

Radiation exposure is the amount of ionizing energy from sources like X-rays, medical treatments, industrial equipment, or nuclear materials that people, products, or environments receive; think of it like sun exposure but from invisible high-energy rays that can damage cells over time. Investors care because excessive exposure can trigger health risks, regulatory fines, facility shutdowns, cleanup costs and liability claims, all of which can affect a company’s operations, reputation and financial outlook.

AI-generated analysis. Not financial advice.

Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences

HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY^® Endovascular Robotic System, announced that it is attending the Society of Interventional Oncology (SIO) annual meeting, being held in Savannah, GA, February 4-8, 2026. The timing of the conference, which is during the Company’s limited market release of the LIBERTY System, will allow the Company to share practical insights and personal experiences from physicians who have used LIBERTY across hospitals and procedure types. This conference also marks the first commercial exhibition of LIBERTY following the commencement of the limited market release in late 2025, permitting the Company to directly engage with interventional oncologists with the goal of accelerating commercial awareness and adoption. Additionally, the Company will feature the LIBERTY System, offering hands-on live demonstrations of the robotic, single-use technology.

“LIBERTY represents a new and differentiated robotic solution, targeting a large and expanding multi-billion dollar market, with interventional oncology serving as a key value driver in interventional radiology,” commented Harel Gadot, CEO, President & Chairman. “Interventional oncology procedure volumes have increased significantly over the past decade, which we believe has created strong demand for advanced technologies such as LIBERTY. Engagement with interventional oncologists, including sharing user experience and reinforcing the breadth of LIBERTY’s functionality, is expected to support the commercial traction of LIBERTY ahead of the full market release which is planned for April.”

The Society of Interventional Oncology is a premier non-profit organization dedicated to establishing interventional oncology (IO) as the fourth pillar of cancer care alongside medical, surgical, and radiation oncology. SIO advances the field through evidence-based research, specialized education, and advocacy, providing a global community for practitioners.

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY System in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY^® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Commercialization Robotics MedTech MBOT News Endovascular Robotics Medical Robotics Innovation SIO

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY^® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical^® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical^® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:
IR@microbotmedical.com
Media@microbotmedical.com

FAQ

Why is Microbot Medical (MBOT) presenting LIBERTY at the SIO conference in February 2026?

To accelerate commercial awareness by sharing physician user experience and hands-on demos. According to the company, the timing during its limited market release lets it engage interventional oncologists and support adoption ahead of a full market release planned for April 2026.

What is the commercial status of the LIBERTY system (MBOT) as of February 5, 2026?

LIBERTY is in a limited market release that began in late 2025. According to the company, the limited release includes physician use across hospitals and procedure types, with a full market release targeted for April 2026 at the SIR conference.

What clinical and operational benefits does LIBERTY (MBOT) claim for interventional oncology procedures?

LIBERTY is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. According to the company, it is the only FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures.

How will hands-on demonstrations at SIO impact MBOT's commercial strategy?

Hands-on demos aim to drive adoption by letting physicians evaluate functionality and workflow fit. According to the company, direct engagement with interventional oncologists is expected to support commercial traction before the full market rollout in April 2026.

When and where does Microbot plan its full market release of LIBERTY (MBOT)?

The company plans a full market release at the Society of Interventional Radiology (SIR) conference in April 2026. According to the company, SIR will be used to showcase LIBERTY broadly to deepen market adoption.